Showing results (31-40 of 66) with videos related to

Sort By:
Pageof 7
Cancers|August 25, 2019
Key Role of Obesity in Genitourinary Tumors with Emphasis on Urothelial and Prostate CancersMatteo Santoni, Alessia Cimadamore, Francesco Massari, et al.
Current Drug Targets|October 19, 2019
Combining Radiotherapy with Immunocheckpoint Inhibitors or CAR-T in Renal Cell CarcinomaMatteo Santoni, Daniel Y C Heng, Gaetano Aurilio, et al.
Future Oncology (London, England)|June 4, 2016
Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancerGaetano Aurilio, Maria Teresa Sandri, Giancarlo Pruneri, et al.
American Journal of Clinical Oncology|February 8, 2006
Capecitabine plus weekly oxaliplatin in gastrointestinal tumors: a phase I studyChiara Carlomagno, Michele Orditura, Stefano Pepe, et al.
Breast Cancer Research and Treatment|February 16, 2013
Role of breast surgery in T1-3 breast cancer patients with synchronous bone metastasesEdoardo Botteri, Elisabetta Munzone, Mattia Intra, et al.
Acta Oncologica (Stockholm, Sweden)|January 19, 2013
Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancerGaetano Aurilio, Lorenzo Monfardini, Stefania Rizzo, et al.
Clinical Breast Cancer|April 25, 2015
Outcome of Immediate Breast Reconstruction in Patients With Nonendocrine-Responsive Breast Cancer: A Monoinstitutional Case-Control StudyGaetano Aurilio, Vincenzo Bagnardi, Franco Nolè, et al.
Cancer Investigation|May 21, 2010
Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer: a phase II studyMichele Orditura, Gennaro Galizia, Vincenzo Napolitano, et al.
European Urology Focus|February 23, 2022
Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase InhibitorsMatteo Santoni, Francesco Massari, Sergio Bracarda, et al.
Clinical Genitourinary Cancer|March 20, 2022
Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World ComparisonMatteo Santoni, Gaetano Aurilio, Francesco Massari, et al.
Pageof 7